Is low-intensity extracorporeal shockwave therapy more effective at improving IIEF-EF score compared to traditional PDE5 inhibitor therapy in the treatment of men with vasogenic erectile dysfunction?

The occurrence of vasogenic erectile dysfunction is strongly correlated to cardiovascular diseases (CVD). PDE5 inhibitors are currently first-line therapy. However, combined use with nitroglycerine, a key therapy in acute coronary syndrome, is contraindicated. The clinical prevalence of CVD with secondary erectile dysfunction necessitate research for alternative therapies.
Purpose: The purpose of this research was to compare the safety and efficacy of current first-line therapy to novel therapy LiESWT in the treatment of vasculogenic erectile dysfunction.
Materials and Methods: Research was conducted using the following: Ovid, PubMed, and Google Scholar. Keywords searched were “Erectile dysfunction”, “Extracorporeal shockwave therapy”, “Erectile function”, “IIEF”, and “Phosphodiesterase 5”. The inclusion criteria included men receiving treatment for ED and excluded meta-analyses or systematic review study designs. Twenty articles met the inclusion criteria. Population groups mainly consisted of men with ED


Jesus Ibarra

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+


agar io


wormax io